Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Investing.com -- Biogen (NASDAQ:BIIB) lowered its full-year outlook to reflect the impact of a $165 million upfront transaction payment to Stoke Therapeutics (NASDAQ:STOK), and reported first-quarter results that beat analyst expectations.
The drugmaker posted Q1 adjusted earnings per share (EPS) of $3.02, topping the $2.96 consensus. Revenue for the period climbed 6% year-over-year to $2.43 billion, also above the $2.23 billion average analyst estimate.
Sales of Leqembi in the U.S., which Biogen markets alongside Eisai, totaled $52 million. The consensus estimate was $54 million, according to Jefferies.
Revenue from multiple sclerosis treatments, including Tecfidera, declined 11% to $953 million. In contrast, sales from Biogen’s rare disease portfolio, which includes Skyclarys and Spinraza, rose 33% to $563 million.
For full-year 2025, Biogen now expects adjusted EPS between $14.50 and $15.50, down from its previous range of $15.25 to $16.25. The revised forecast includes a $0.95 negative impact from a $165 million upfront payment to Stoke Therapeutics, partially offset by a $0.20 benefit from foreign exchange.
The company continues to project a mid-single-digit revenue decline at constant currency compared to 2024, but said the underlying business outlook remains unchanged.
Biogen added that the updated guidance does not factor in potential impacts from U.S. tariffs announced on April 2. While the company noted the tariff environment remains uncertain, it said even the removal of exemptions for pharmaceuticals is not currently expected to materially affect its 2025 outlook.